REFERENCES
1. Qin Y, Tang C, Li J, Gong J. Liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021. BMC Cancer. 2024;24:594.
2. Shen C, Jiang X, Li M, Luo Y. Hepatitis virus and hepatocellular carcinoma: recent advances. Cancers. 2023;15:533.
3. Oncology Society of Chinese Medical Association. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]. Zhonghua Zhong Liu Za Zhi. 2024;46:805-43.
4. Sharma S. Benefits or concerns of AI: a multistakeholder responsibility. Futures. 2024;157:103328.
5. Yüksel N, Börklü HR, Sezer HK, Canyurt OE. Review of artificial intelligence applications in engineering design perspective. Eng Appl Artif Intell. 2023;118:105697.
6. Sarker IH. Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. SN Comput Sci. 2021;2:420.
7. Mienye ID, Swart TG, Obaido G, Jordan M, Ilono P. Deep convolutional neural networks in medical image analysis: a review. Information. 2025;16:195.
8. Nguyen-Tat TB, Hung TQ, Nam PT, Ngo VM. Evaluating pre-processing and deep learning methods in medical imaging: combined effectiveness across multiple modalities. Alex Eng J. 2025;119:558-86.
9. Xia TY, Zhou ZH, Meng XP, et al. Predicting microvascular invasion in hepatocellular carcinoma using CT-based radiomics model. Radiology. 2023;307:e222729.
10. Bae JS, Lee HH, Kim H, Song IC, Lee JY, Han JK. Deep learning-aided 1H-MR spectroscopy for differentiating between patients with and without hepatocellular carcinoma. Magn Reson Med Sci. 2025:mp.2025-0064.
11. Hou J, Berg T, Vogel A, et al. Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies. JHEP Rep. 2025;7:101263.
12. Potter LN, Yap J, Dempsey W, Wetter DW, Nahum-Shani I. Integrating intensive longitudinal data (ILD) to inform the development of dynamic theories of behavior change and intervention design: a case study of scientific and practical considerations. Prev Sci. 2023;24:1659-71.
13. Hao S, Lin S, Wang J, Zhong Q. Dynamic modeling for multivariate functional and longitudinal data. J Econometrics. 2024;239:105573.
14. Diao S, Tian Y, Hu W, et al. Weakly supervised framework for cancer region detection of hepatocellular carcinoma in whole-slide pathologic images based on multiscale attention convolutional neural network. Am J Pathol. 2022;192:553-63.
15. Banerjee T, Singh DP, Kour P, et al. A novel unified Inception-U-Net hybrid gravitational optimization model (UIGO) incorporating automated medical image segmentation and feature selection for liver tumor detection. Sci Rep. 2025;15:29908.
16. Prajumwongs P, Titapun A, Thanasukarn V, et al. Serum peptide biomarkers by MALDI-TOF MS coupled with machine learning for diagnosis and classification of hepato-pancreato-biliary cancers. Sci Rep. 2025;15:29169.
17. Zhang G, Peng Z, Yan C, Wang J, Luo J, Luo H. A novel liver cancer diagnosis method based on patient similarity network and DenseGCN. Sci Rep. 2022;12:6797.
18. Sucularli C. Machine learning-based identification of diagnostic and prognostic mitotic cell cycle genes in hepatocellular carcinoma. PLoS One. 2025;20:e0331118.
19. Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2023;12:216-28.
20. Xu X, Li J, Zhu Z, et al. A comprehensive review on synergy of multi-modal data and AI technologies in medical diagnosis. Bioengineering. 2024;11:219.
21. Yang T, Wang MD, Xu XF, Li C, Wu H, Shen F. Management of hepatocellular carcinoma in China: seeking common grounds while reserving differences. Clin Mol Hepatol. 2023;29:342-4.
22. Xu Y, Xia C, Li H, et al. Survey of hepatitis B virus infection for liver cancer screening in China: a population-based, cross-sectional study. Chin Med J. 2024;137:1414-20.
23. Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42:2029-41.
25. Wang X, Zhang Y, Yang N, et al. Evaluation of the combined application of AFP, AFP-L3%, and DCP for hepatocellular carcinoma diagnosis: a meta-analysis. Biomed Res Int. 2020;2020:5087643.
26. Tu X, He Z, Huang Y, Zhang Z, Yang M, Zhao J. An overview of large AI models and their applications. Vis Intell. 2024;2:65.
27. Alqahtani T, Badreldin HA, Alrashed M, et al. The emergent role of artificial intelligence, natural learning processing, and large language models in higher education and research. Res Social Adm Pharm. 2023;19:1236-42.
28. Yu X, Lei X. Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer. Diagnostics. 2023;13:2484.
29. Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9:682-720.
30. El Atifi W, El Rhazouani O, Khan FM, Sekkat H. Optimizing ensemble machine learning models for accurate liver disease prediction in healthcare. PLoS One. 2025;20:e0330899.
31. Sang H, Lee H, Lee M, et al. Prediction model for cardiovascular disease in patients with diabetes using machine learning derived and validated in two independent Korean cohorts. Sci Rep. 2024;14:14966.
32. Abdelhamed W, El-Kassas M. Integrating artificial intelligence into multidisciplinary evaluations of HCC: opportunities and challenges. Hepatoma Res. 2025;11:8.
33. Seven İ, Bayram D, Arslan H, et al. Predicting hepatocellular carcinoma survival with artificial intelligence. Sci Rep. 2025;15:6226.
34. Zhang ZM, Huang Y, Liu G, et al. Development of machine learning-based predictors for early diagnosis of hepatocellular carcinoma. Sci Rep. 2024;14:5274.
35. Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current imaging diagnosis of hepatocellular carcinoma. Cancers. 2022;14:3997.
36. Vengateswaran HT, Habeeb M, You HW, Aher KB, Bhavar GB, Asane GS. Hepatocellular carcinoma imaging: exploring traditional techniques and emerging innovations for early intervention. Med Nov Technol Devices. 2024;24:100327.
37. Tu J, Wang B, Wang X, et al. Current status and new directions for hepatocellular carcinoma diagnosis. Liver Res. 2024;8:218-36.
38. Romeo M, Dallio M, Napolitano C, et al. Clinical applications of artificial intelligence (AI) in human cancer: is it time to update the diagnostic and predictive models in managing hepatocellular carcinoma (HCC)? Diagnostics. 2025;15:252.
39. Chatzipanagiotou OP, Loukas C, Vailas M, et al. Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature. J Gastroenterol Hepatol. 2024;39:1994-2005.
40. Liu Z, Liu Y, Hong Y, et al. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. arXiv 2021;arXiv:2106.00090. Available from: https://doi.org/10.48550/arXiv.2106.00090 [accessed 18 Dec 2025].
41. Ennab M, Mcheick H. Enhancing interpretability and accuracy of AI models in healthcare: a comprehensive review on challenges and future directions. Front Robot AI. 2024;11:1444763.
42. Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Mol Cancer. 2025;24:159.
43. Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell. 2025;43:708-27.
44. Richter M, Emden D, Leenings R, et al.; MBB consortium, FOR2107 consortium, PRONIA consortium. Generalizability of clinical prediction models in mental health. Mol Psychiatry. 2025;30:3632-9.
45. Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability in clinical research and machine learning in health care. Lancet Digit Health. 2020;2:e489-92.
46. Yang J, Soltan AAS, Clifton DA. Machine learning generalizability across healthcare settings: insights from multi-site COVID-19 screening. NPJ Digit Med. 2022;5:69.
47. Chang Q, Yan Z, Zhou M, et al. Mining multi-center heterogeneous medical data with distributed synthetic learning. Nat Commun. 2023;14:5510.
48. Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54:890-901.
49. Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: a state-of-the-art review. World J Gastrointest Oncol. 2021;13:1599-615.
50. Jiang C, Cai YQ, Yang JJ, et al. Radiomics in the diagnosis and treatment of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2023;22:346-51.
51. Avery E, Sanelli PC, Aboian M, Payabvash S. Radiomics: a primer on processing workflow and analysis. Semin Ultrasound CT MR. 2022;43:142-6.
52. Dong D, Liu S, Liu Z, et al. Radiomics and multiomics research. In: Liu S, editor. Artificial intelligence in medical imaging in China. Singapore: Springer Nature; 2024. pp. 63-81.
53. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-62.
54. Gurzu S, Szodorai R, Jung I, Banias L. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies. J Cancer Res Clin Oncol. 2024;150:270.
55. An L, Zheng R, Zhang S, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr. 2023;12:45-55.
56. Mirbabaie M, Stieglitz S, Frick NRJ. Artificial intelligence in disease diagnostics: a critical review and classification on the current state of research guiding future direction. Health Technol. 2021;11:693-731.
57. Midya A, Chakraborty J, Srouji R, et al. Computerized diagnosis of liver tumors from CT scans using a deep neural network approach. IEEE J Biomed Health Inform. 2023;27:2456-64.
58. Stollmayer R, Budai BK, Tóth A, et al. Diagnosis of focal liver lesions with deep learning-based multi-channel analysis of hepatocyte-specific contrast-enhanced magnetic resonance imaging. World J Gastroenterol. 2021;27:5978-88.
59. Maniaci A, Lavalle S, Gagliano C, et al. The integration of radiomics and artificial intelligence in modern medicine. Life 2. 24;14:1248.
60. Youssef A, Pencina M, Thakur A, Zhu T, Clifton D, Shah NH. External validation of AI models in health should be replaced with recurring local validation. Nat Med. 2023;29:2686-7.
61. Khalifa M, Albadawy M. AI in diagnostic imaging: revolutionising accuracy and efficiency. Comput Methods Programs Biomed Update. 2024;5:100146.
62. Vrettos K, Triantafyllou M, Marias K, Karantanas AH, Klontzas ME. Artificial intelligence-driven radiomics: developing valuable radiomics signatures with the use of artificial intelligence. BJR AI. 2024;1:ubae011.
63. Yan T, Yu L, Zhang N, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biol Med. 2022;19:802-17.
64. Chan YT, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23:189.
65. Nair M, Sandhu SS, Sharma AK. Cancer molecular markers: a guide to cancer detection and management. Semin Cancer Biol. 2018;52:39-55.
66. Dwivedi YK, Hughes L, Ismagilova E, et al. Artificial intelligence (AI): multidisciplinary perspectives on emerging challenges, opportunities, and agenda for research, practice and policy. Int J Inf Manag. 2021;57:101994.
67. Gao K, Yaermaimaiti M, Wang Y, Xia G, Xu T, Wang H. Bi-regional machine learning radiomics based on CT noninvasively predicts LOX expression level and overall survival in hepatocellular carcinoma. Cancer Med. 2025;14:e71154.
68. Cheng B, Deng H, Zhao Y, et al. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation. Eur Radiol. 2022;32:5869-79.
69. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
70. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
71. Li S, Li XG, Zhou F, et al. Automated segmentation of liver and hepatic vessels on portal venous phase computed tomography images using a deep learning algorithm. J Appl Clin Med Phys. 2024;25:e14397.
72. Memeo R, Conticchio M, Deshayes E, et al. Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr. 2021;10:350-63.
73. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79:1180-211.
74. Zeng X, Tao H, Dong Y, et al. Impact of three-dimensional reconstruction visualization technology on short-term and long-term outcomes after hepatectomy in patients with hepatocellular carcinoma: a propensity-score-matched and inverse probability of treatment-weighted multicenter study. Int J Surg. 2024;110:1663-76.
75. Zeng L, Zhu Y, Guo P. Meta-analysis of the effects of three-dimensional visualized medical techniques hepatectomy for liver cancer with and without the treatment of sorafenib. Evid Based Complement Alternat Med. 2022;2022:4507673.
76. Chansangrat J, Gadani S. Radioembolization for hepatocellular carcinoma: updated strategies and evolving clinical applications. Hepatoma Res. 2024;10:49.
77. Yang Y, Yu H, Qi L, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia. 2022;39:455-65.
78. Bartnik K, Krzyziński M, Bartczak T, et al. A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation. Sci Rep. 2024;14:14779.
79. Kokabi N, Arndt-Webster L, Chen B, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50:1743-52.
80. Bibault JE, Giraud P. Deep learning for automated segmentation in radiotherapy: a narrative review. Br J Radiol. 2024;97:13-20.
81. Lee CL, Freeman M, Burak KW, et al. Real-world outcomes of atezolizumab with bevacizumab treatment in hepatocellular carcinoma patients: effectiveness, esophagogastroduodenoscopy utilization and bleeding complications. Cancers. 2024;16:2878.
82. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
83. Kinsey E, Lee HM. Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape. Cancers. 2024;16:666.
84. Xu F, Zhang H, Chen J, et al. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease. J Ethnopharmacol. 2024;321:117514.
85. Guan Y, He Q. Liver cancer: Zheng classification of Qi stagnation and blood stasis. Pharmacol Pharm. 2014;5:75-82.
86. Gu Z, Qi X, Zhai X, et al. Study on TCM syndrome differentiation of primary liver cancer based on the analysis of latent structural model. Evid Based Complement Alternat Med. 2015;2015:761565.
87. Yang SR, Chen L, Luo D, Wang YY, Liang FX. Unlocking the potential: how acupuncture reshapes the liver-centered lipid metabolism pattern to fight obesity. J Integr Med. 2024;22:523-32.
88. Lei Y, Chen C. Bibliometric analysis of traditional Chinese medicine in cancer treatment via immune system modulation (2015-2025). Front Immunol. 2025;16:1581885.
89. Zhang H, Dai Q, Zeng M, et al. Investigating the metabolic level of endogenous and Exogenous Substances On The Intervention Of Traditional Chinese medicine Fuzheng Yiliu Decoction in a rat orthotopic liver cancer model. Cancer Manag Res. 2022;14:2785-801.
90. Zhang JX, Bao SC, Chen J, et al. Xiaojianzhong decoction prevents gastric precancerous lesions in rats by inhibiting autophagy and glycolysis in gastric mucosal cells. World J Gastrointest Oncol. 2023;15:464-89.
91. Zhang L, Yang JX, Li XH, Zhang XY, Wang HJ. Effect of modified Huqi prescription on quality of life in patients with primary liver cancer of Zhengqi deficiency and toxin-stasis binding syndrome after transcatheter arterial chemoembolization: a retrospective cohort study. J Tradit Chinese Med. 2019;60:306-10.
92. Yu YX, Wang S, Liu ZN, et al. Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions. Chin Med. 2023;18:59.
93. Zao X, Cao X, Liang Y, et al. The Chinese herbal KangXianYiAi formula inhibits hepatocellular carcinoma by reducing glutathione and inducing ferroptosis. Pharmacol Res Mod Chin Med. 2023;8:100276.
94. Ge Y, Shi X, Zhang W, et al. Effect of the self-designed peiyuan jiedu tongluo decoction combined with conventional western medicine on postoperative syndrome of liver cancer patients treated with transcatheter arterial chemoembolization. Hebei Med J. 2023;45:3581-3.
95. Han L, Ma Y, Wu W, et al. Research progress on the therapeutic effects of effective components of traditional Chinese medicine in the treatment of gastric cancer precursors through modulation of multiple signaling pathways. Front Oncol. 2025;15:1555274.
96. Bilal M, Hamza A, Malik N. NLP for analyzing electronic health records and clinical notes in cancer research: a review. J Pain Symptom Manage. 2025;69:e374-94.
97. Shi Z, Wu B, Hu B, et al. A large language model for clinical outcome adjudication from telephone follow-up interviews: a secondary analysis of a multicenter randomized clinical trial. Nat Commun. 2025.
98. Zhang H, Zhang Z, Zhang K, Gao Z, Shen Z, Shen W. CT-based deep learning radiomics model for predicting proliferative hepatocellular carcinoma: application in transarterial chemoembolization and radiofrequency ablation. BMC Med Imaging. 2025;25:363.
99. Liang J, Weng S, Zhang J, et al. Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI. Eur J Nucl Med Mol Imaging. 2025;52:3951-62.
100. Rompianesi G, Pegoraro F, Ceresa CD, Montalti R, Troisi RI. Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases. World J Gastroenterol. 2022;28:108-22.
101. Magrabi F, Ammenwerth E, McNair JB, et al. Artificial intelligence in clinical decision support: challenges for evaluating AI and practical implications. Yearb Med Inform. 2019;28:128-34.
102. Tan S, Xin X, Wu D. ChatGPT in medicine: prospects and challenges: a review article. Int J Surg. 2024;110:3701-6.
103. Hou H, Zhang R, Li J. Artificial intelligence in the clinical laboratory. Clin Chim Acta. 2024;559:119724.
